CVS Health Reports Strong Q1 Results, Raises Full-Year 2026 EPS and Cash Flow Guidance
CVS sits 44% above its 52-week low of $58.35.
Summary
CVS Health announced strong first-quarter 2026 results, with significant increases in revenue and EPS, and raised its full-year 2026 guidance for both GAAP and Adjusted EPS, as well as cash flow from operations.
Key Events · Earnings and Guidance · CVS
-
Strong Q1 2026 Financial Performance
Total revenues increased 6.2% year-over-year to $100.4 billion. GAAP diluted EPS rose to $2.30 from $1.41, and Adjusted EPS increased to $2.57 from $2.25 in the prior year's first quarter.
-
Raised Full-Year 2026 EPS Guidance
The company increased its full-year 2026 GAAP diluted EPS guidance range to $6.24-$6.44 (from $5.94-$6.14) and Adjusted EPS guidance range to $7.30-$7.50 (from $7.00-$7.20).
-
Increased Full-Year Cash Flow Guidance
CVS Health also raised its full-year 2026 cash flow from operations guidance to at least $9.5 billion, up from at least $9.0 billion previously.
-
Operational Improvements Driving Results
The improved performance was primarily driven by strong execution in the Health Care Benefits segment, reflecting progress on its margin recovery plan, and growth across all operating segments.
Analysis · CVS · Trade & Services
CVS Health's strong first-quarter performance and increased full-year guidance signal a significant positive shift, especially following the substantial net income and EPS decline reported in the 2025 annual report. The raised Adjusted EPS forecast, now $7.30-$7.50, and increased cash flow from operations guidance to at least $9.5 billion, demonstrate robust operational execution and improved financial health. This positive momentum, occurring while the stock trades near its 52-week high, reinforces investor confidence and suggests the company is effectively navigating industry challenges and executing its strategic initiatives.
At the time of this filing, CVS was trading at $83.98 on NYSE in the Trade & Services sector, with a market capitalization of approximately $103.4B. The 52-week trading range was $58.35 to $85.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.